Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
November 01 2024 - 8:30AM
Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused
on addressing significant unmet needs of women worldwide with a
broad portfolio of in-office, accessible, and innovative
therapeutic and diagnostic products, announces that the United
States Patent and Trademark Office (“USPTO”) issued U.S. Patent No.
12,12796 covering FemBloc® permanent birth control. This further
strengthens Femasys’ intellectual property position and coverage
for FemBloc, the Company’s leading therapeutic product candidate.
The issued patent has an anticipated expiration in 2039 at the
earliest. Femasys intends to continue to prosecute additional
patent applications to further enhance its existing patent
portfolio protecting FemBloc, along with the Company’s existing
available therapeutic product, FemaSeed® intratubal insemination
for infertility treatment, and diagnostic products, FemVue®,
FemCath®, FemCerv®, and FemChec®.
“The issuance of claims for the FemBloc permanent birth control
is another important milestone in protecting the commercial
potential for this novel, non-surgical contraceptive option for
women seeking a permanent birth control solution, which is
currently enrolling subjects in its pivotal clinical trial,” stated
Kathy Lee-Sepsick, CEO of Femasys. “Expansion of our patent
portfolio, which consists of over 180 patents globally,
demonstrates our continued unwavering commitment to protecting the
innovation and commercial opportunity of our entire suite of
products for women seeking better and more accessible options.”
About FemBloc
FemBloc® is a first-of-its-kind, nonsurgical, non-implant,
in-office solution in its late-stage of clinical development for
permanent birth control. It is intended to be a safer option for
women estimated at approximately half the cost of the long-standing
surgical alternative by eliminating the need for anesthesia,
incisions, and permanent implants. FemBloc has the potential to
offer women a convenient, accessible, and reliable option for those
seeking permanent birth control. For over 100 years there has been
stagnant innovation for permanent birth control which could lead to
a $20 billion market expansion opportunity for FemBloc in the U.S.
alone. For more information, visit www.FemBloc.com.
About FemasysFemasys is a leading biomedical
company focused on addressing significant unmet needs of women
worldwide with a broad portfolio of in-office, accessible, and
innovative therapeutic and diagnostic solutions, including a lead
revolutionary product candidate and FDA-cleared products.
FemaSeed® Intratubal Insemination, an innovative infertility
treatment designed to deliver sperm directly where conception
occurs, is FDA-cleared and has received regulatory approval in
Canada and Europe. FemBloc® permanent birth control in
late-stage clinical development is the first and only non-surgical,
in-office, permanent birth control method intended to be a safer
option for women at substantially less cost than the long-standing
surgical alternative. The Company has developed diagnostic products
that are complementary for which it has achieved regulatory
approvals to market in the U.S., Canada, Europe, and other ex-U.S.
territories, and which are commercial-ready due to its in-house
manufacturing capabilities. Its diagnostic products include
FemVue® and FemVue® MINI for fallopian tube assessment by
ultrasound, which can be used in conjunction with FemCath®, an
intrauterine catheter for selective fallopian tube evaluation, and
FemCerv®, an endocervical tissue sampler for cervical cancer
diagnosis. Learn more at www.femasys.com, or follow us on X,
Facebook and LinkedIn.
This press release contains forward-looking statements that are
subject to substantial risks and uncertainties. Forward-looking
statements can be identified by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “pending,”
“intend,” “believe,” “suggests,” “potential,” “hope,” or “continue”
or the negative of these terms or other similar expressions,
although not all forward-looking statements contain these words.
Forward-looking statements are based on our current expectations
and are subject to inherent uncertainties, risks and assumptions,
many of which are beyond our control, difficult to predict and
could cause actual results to differ materially from what we
expect. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be
accurate. Factors that could cause actual results to differ
include, among others: our ability to develop and advance our
current product candidates and programs into, and successfully
initiate, enroll and complete, clinical trials; the ability of our
clinical trials to demonstrate safety and effectiveness of our
product candidates and other positive results; estimates regarding
the total addressable market for our products and product
candidates; our ability to commercialize our products and product
candidates, or the effect of delays in commercializing our
products, including FemaSeed; our business model and strategic
plans for our products, technologies and business, including our
implementation thereof; and those other risks and uncertainties
described in the section titled "Risk Factors" in our Annual Report
on Form 10-K for the year ended December 31, 2023, and other
reports as filed with the SEC. Forward-looking statements contained
in this press release are made as of this date, and Femasys
undertakes no duty to update such information except as required
under applicable law.
Contacts:
Investors:Matt BlazeiIR@femasys.com
Media Contact:Kati WaldenburgMedia@femasys.com
Femasys (NASDAQ:FEMY)
Historical Stock Chart
From Nov 2024 to Dec 2024
Femasys (NASDAQ:FEMY)
Historical Stock Chart
From Dec 2023 to Dec 2024